Utrogestan 100 mg 30 capsules — Made in Belgium — Free Delivery

Brand: Besins Healthcare
Product Code: Utrogestan 200 mg
Availability: In Stock

$49.27

Add to Cart

Description

Product description

Capsules "Utrogestan®" are used for the indications listed below.

Progesterone deficiency disorders.

Oral administration

Gynecological:

disorders associated with a deficiency of progesterone, namely:
premenstrual syndrome;
violation of the menstrual cycle (disovulation, anovulation);
fibrocystic breast disease;
premenopausal period;
hormone replacement therapy in menopause (in combination with estrogen therapy);
infertility with luteal insufficiency;

Obstetric:

prevention of habitual miscarriage or the threat of miscarriage against the background of luteal insufficiency;
the threat of premature birth.
Intravaginal use
decreased fertility in primary or secondary infertility with partial or complete luteal insufficiency (disovulation, support of the luteal phase during preparation for in vitro fertilization, egg donation program); prevention of habitual miscarriage or the threat of spontaneous miscarriage in case of luteal insufficiency;
prevention of premature birth in women with a short cervix or in women with a history of premature spontaneous labor;
impossibility or limitation of ingestion of the preparation.

Composition

The active ingredient is progesterone (one capsule contains 100 mg micronized progesterone).

Excipients: sunflower oil, soy lecithin, gelatin, glycerin, titanium dioxide (E 171), purified water.

Contraindications

hypersensitivity to the components of the preparation;
severe liver dysfunctions;
suspected or confirmed breast or genital neoplasia;
undiagnosed vaginal bleeding;
unsuccessful or incomplete abortion;
thrombophlebitis;
thromboembolic disorders;
cerebral hemorrhage;
porphyria.

Mode of application

The duration of treatment depends on the nature of the disease.

Oral administration

In most cases, the average daily dose is 200-300 mg in 1 or 2 divided doses (200 mg in the evening, before bedtime, and 100 mg in the morning, if necessary).

In case of insufficiency of the luteal phase (premenstrual syndrome, menstrual irregularities, premenopause, fibrocystic breast disease): take within 10 days (usually from the 17th to the twenty-sixth day of the cycle, inclusive).

With hormone replacement therapy for menopause: since estrogen therapy alone is not recommended, progesterone must be used as an adjunct to it for the last 2 weeks of each course, which follow one week of support for any replacement therapy, during which withdrawal bleeding may occur.

With the threat of premature birth: take 400 mg of the preparation "Utrogestan®" every 6-8 hours until the symptoms disappear. The effective dose and frequency of use are selected individually, depending on the clinical manifestations of the threat of premature birth. After the symptoms disappear, the dose of the preparation "Utrogestan®" is gradually reduced to a maintenance dose (for example, 200 mg 3 times a day). At this dose, the preparation can be used up to 36 weeks of pregnancy.

The use of progesterone after 36 weeks of pregnancy is not recommended.

Intravaginal use

Insert the capsules deep into the vagina while lying on your back.

Before each use of the preparation, you must thoroughly wash your hands so that there is no detergent left on your hands.

On average, the dose is 200 mg of progesterone per day (one 200 mg capsule or two 100 mg capsules, in 2 doses, in the morning and in the evening, which are inserted deep into the vagina, if necessary, using an applicator). The dose can be increased depending on the patient's response.

With partial insufficiency of the luteal phase (disovulation, menstrual irregularities), the daily dose is 200 mg for 10 days (usually from the 17th to the twenty-sixth day of the cycle).

With complete insufficiency of the luteal phase (complete absence of progesterone in women with non-functioning (absent) ovaries (egg donation)): the dose of progesterone is 100 mg on the thirteenth and fourteenth days of the transfer cycle. From the 15th to the twenty-fifth day of the cycle, the dose of progesterone is 200 mg, divided into two doses (morning and evening). Starting from the 26th day, in case of early diagnosis of pregnancy, the dose is increased gradually (every week) by 100 mg of progesterone per day, reaching a maximum of 600 mg of progesterone per day, divided into three doses. This dosage should be observed until the 60th day.

Luteal phase support during the in vitro fertilization cycle: treatment is carried out starting from the evening of the day of embryo transfer, at the rate of 600 mg per day in 3 divided doses (200 mg once every 8 hours).

Prevention of premature birth in women with a short cervix or in women with a history of premature spontaneous labor: the dose is 200 mg per day and is applied in the evening before bedtime from 22nd to 36th week of pregnancy.

Application features

Pregnant

The use of the preparation "Utrogestan®" is not contraindicated during pregnancy, including in the first weeks. During the period of use of the preparation, not a single case of adverse effect of the preparation on the fetus was observed. When using the preparation in the second and third trimesters of pregnancy, monitoring of liver function is necessary.

The release of progesterone into breast milk has not been studied in detail. Therefore, its appointment should be avoided during breastfeeding.

There is evidence of the possible development of hypospadias when progestogens are used during pregnancy to prevent a common miscarriage or the threat of miscarriage against the background of luteal insufficiency, which the patient should be informed about.

Children

There are no clinical data on the use of the preparation in children.

Drivers

Transport drivers and machine operators: possible drowsiness and dizziness associated with taking the preparation internally. The use of capsules at bedtime avoids these unpleasant consequences. Cases of drowsiness and dizziness were observed only with oral administration of the preparation.

Overdose

Overdose symptoms can be manifested by symptoms of adverse reactions, including drowsiness, dizziness, euphoria, dysmenorrhea, decreased cycle duration, metrorrhagia.

In some individuals, the usual dose may be excessive due to the existing or secondary appearance of unstable endogenous progesterone secretion, hypersensitivity to the preparation, or very low concomitant blood estradiol levels.

In such cases, it is enough:

reduce the dose of progesterone or prescribe progesterone in the evening before bedtime for 10 days per cycle in case of drowsiness or fleeting dizziness;

postpone the start of treatment to a later date in the cycle in case of its reduction or bleeding;

check if the level of estradiol is sufficient in a patient who is receiving hormone replacement therapy in premenopausal women.

Side effects

Frequent (> 1/100; <1/10) side effects that were observed with oral administration:

disorders of the reproductive system and mammary glands: changes in menstruation, amenorrhea, intermittent bleeding;

violation of the central nervous system: headaches.

With vaginal use of the preparation, hypersensitivity reactions are possible, including burning, itching, hyperemia, as well as the appearance of oily discharge.

Storage conditions

Store at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 3 years.

0 reviews

There are no reviews for this product.